Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284827 | 1.00 | TOP2A (0.39) | TOP2AHDAC1DUTBCHE | |
| SCHEMBL12373094 | 0.91 | TOP2A (0.36) | TOP2AHDAC1DUTBCHE | |
| SCHEMBL2284113 | 0.86 | TK1 (0.39) | — | |
| SCHEMBL12373120 | 0.86 | TK1 (0.39) | — | |
| SCHEMBL2282272 | 0.84 | BCHE (0.32) | TOP2ABCHE | |
| SCHEMBL12373119 | 0.80 | BCHE (0.31) | BCHE | |
| SCHEMBL12373095 | 0.80 | TOP2A (0.47) | TOP2AHDAC1DUTBCHE | |
| SCHEMBL14217397 | 0.78 | TK1 (0.33) | — | |
| SCHEMBL30848702 | 0.78 | LMNA (0.47) | TOP2AHDAC1DUTBCHE | |
| SCHEMBL2284865 | 0.77 | TOP2A (0.57) | TOP2AHDAC1DUTBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | Life Technologies Corporation (US) | 2012-12-06 | — | — | US | disclosed |
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| US-20050170388-A1 | Pyrimidine nucleobases | APPLERA CORPORATION (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | PNP, NT5C3B, NUDT1 | TOP2A 255/4885HDAC1 2798/4885DUT 5/4885 |
| US-20050170388-A1 | Pyrimidine nucleobases | DPYD, PNP, UMPS | TOP2A 324/4885HDAC1 3613/4885DUT 6/4885 |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | PNP, NUDT1, DUT | TOP2A 364/4885HDAC1 2715/4885DUT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.